IXHL (Incannex Healthcare) Other Gross PPE : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Incannex Healthcare Other Gross PPE?

Incannex Healthcare's Other Gross PPE for the quarter that ended in Dec. 2024 was $0.00 Mil.

Incannex Healthcare Other Gross PPE Historical Data

The historical data trend for Incannex Healthcare's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incannex Healthcare Other Gross PPE Chart

Incannex Healthcare Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Other Gross PPE

Get a 7-Day Free Trial

Incannex Healthcare Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Gross PPE	Get a 7-Day Free Trial															-	-	-	-	-

Incannex Healthcare Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Incannex Healthcare Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Incannex Healthcare Inc (NAS:IXHL) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 Century Circuit Norwest, Suite 105, Sydney, NSW, AUS, 3000

Website

https://www.incannex.com.au

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.